« Back
Home /
Obinutuzumab (anti-CD20)

Obinutuzumab (anti-CD20)

Item no.	A2023-1mg
Manufacturer	Selleckchem
CASRN	949142-50-1
Amount	1 mg
Quantity options	1 mg 1 mg x 25 1 mg x 5
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Bladder Cancer Gastric Cancer
Type	Inhibitors
Specific against	other
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Gazyva,GA101,Gazyvaro,Afutuzumab
Available
Storage Conditions	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
Information	Obinutuzumab (anti-CD20) (Gazyva, GA101, Gazyvaro, Afutuzumab) is a novel, type II, glycoengineered, humanized anti-CD20 monoclonal antibody that has been developed for lymphocytic leukemia and lymphoma of B-cell origin. MW : 146.1 kD.
Pathway	Transmembrane Transporters

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

A2023-1mg-datasheet.pdf

A2023-1mg-safety-datasheet.pdf